z-logo
open-access-imgOpen Access
Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy
Author(s) -
Belinda M. Kumpel,
Radka Saldova,
Carolien A. M. Koeleman,
Jodie L. Abrahams,
Agnes L. Hipgrave Ederveen,
Kathryn L. Armour,
Н. И. Оловникова,
Gestur Vidarsson,
Rick Kapur,
Pauline M. Rudd,
Manfred Wuhrer
Publication year - 2020
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-019-57393-9
Subject(s) - fucosylation , antibody dependent cell mediated cytotoxicity , monoclonal antibody , chinese hamster ovary cell , microbiology and biotechnology , antibody , glycosylation , chemistry , cell culture , immunoglobulin g , biology , immunology , biochemistry , receptor , fucose , glycoprotein , genetics
Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in FcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting ADCC activity. In vivo , two B mAb-Ds with 77–81% fucosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig. High fucosylation (>89%) of mouse-human heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat YB2/0 mAb-Ds with <50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. Galactosylation of B mAb-Ds was 57–83% but 15–58% for rodent mAb-Ds. HH mAb-Ds had non-human sugars. These data reveal high galactosylation like anti-D Ig (>60%) together with lower fucosylation (<60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable effective, inexpensive prophylaxis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here